Table 2.
Baseline characteristics of the participants a
| Variable | Olive Oil group (n = 22) | Canola Oil group (n = 20) | P-value b |
|---|---|---|---|
| Age (year) | 55.09 ± 6.92 | 59.30 ± 5.84 | 0.44 |
| Sex (Male) | 20 (91%) | 18 (90%) | 0.66 |
| PCI history | 16 (73%) | 16 (80%) | 0.89 |
| CABG history | 2 (9.1%) | 1 (5%) | 0.86 |
| Diabetes Mellitus | 8 (36%) | 8 (40%) | 0.91 |
| Hypertension | 11 (50%) | 11 (55%) | 0.92 |
| Dyslipidemia | 12 (54%) | 8 (40%) | 0.55 |
| Overweight | 16 (73%) | 11 (55%) | 0.19 |
| Smoking | 8 (36%) | 4 (20%) | 0.30 |
| Medications: | |||
| Aspirin | 21 (95%) | 20 (100%) | 0.93 |
| Clopidogrel | 15 (68%) | 10 (50%) | 0.29 |
| Statins | 20 (91%) | 19 (95%) | 0.93 |
| ACEI | 9 (41%) | 4 (20%) | 0.12 |
| ARB | 10 (45%) | 13 (65%) | 0.42 |
| BB | 15 (68%) | 15 (75%) | 0.81 |
| Nitrates | 7 (31%) | 7 (35%) | 0.90 |
| Aldosteron Antagonist | 5 (22%) | 1 (5%) | 0.17 |
aData presentedas Mean ± SD or number (percentage)
bData were compared using Independent t-testor Chi-square test
PCI Percutaneous Coronary Intervention, CABG Coronary Artery Bypass Graft, ACEI Angiotensin Converting Enzyme Inhibitor, ARB Angiotensin Receptor Blocker, BB Beta-Blocker